FDA approved generic Iron Sucrose Injection for Amphastar Pharmaceuticals on September 2, 2025.
4 reports, 4 independent
Updated Sep 2
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved generic Iron Sucrose Injection for Amphastar Pharmaceuticals on September 2, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA granted approval for generic Iron Sucrose Injection to Amphastar.1 source
Viatris appoints Andrew Enrietti amid ongoing FDA approval of Iron Sucrose Injection.1 source
Keep exploring
The entities involved
- FDA
-
Amphastar Pharmaceuticals
publicly traded American pharmaceutical company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyAmphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Amphastar Pharm
- Simply Wall St.Will Viatris’ (VTRS) New Transformation Role Accelerate Its Operational and Cultural Overhaul? On August 19, 2025, Viatris Inc. announced it had appointed Andrew Enrietti as Chief Administrative and
- BenzingaAmphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH)
- ACCESS NewswireAmphastar Announces FDA Approval for Iron Sucrose Injection, USP According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer&